Comparison · NCT01651949-sae
Heterosexual and MSM Males vs Females: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Heterosexual and MSM Males vs Females: serious adverse events. Trial comparisons, record NCT01651949-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01651949-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0165 | 0.011 | 0.0246 | wilson | |
| Risk in group 2 | 0.0242 | 0.0166 | 0.0352 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00769 | -0.02 | 0.00347 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.682 | 0.391 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 0.677 | 0.384 | 1.19 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Heterosexual and MSM Males than on Females | 130 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Heterosexual and MSM Males | Healthy heterosexual and MSM males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6 | 23 | 1,394 | EG000 |
| Group 2 | Females | Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6 | 26 | 1,075 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to Month 12
Source ClinicalTrials.gov
Trial
- Title
- Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
- NCT number
- NCT01651949
- Phases
- PHASE3
- Conditions
- Genital Warts, Anal Cancer, Anal Intraepithelial Neoplasia
- Interventions
- 9vHPV Vaccine
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2015-03-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01651949?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01651949-sae